Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Common Equity (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Common Equity for 5 consecutive years, with -$337.0 million as the latest value for Q1 2026.

  • For Q1 2026, Common Equity changed 0.42% year-over-year to -$337.0 million; the TTM value through Mar 2026 reached -$337.0 million, changed 0.42%, while the annual FY2025 figure was -$438.2 million, 72.79% down from the prior year.
  • Common Equity hit -$337.0 million in Q1 2026 for Phathom Pharmaceuticals, up from -$438.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $38.0 million in Q1 2022 and bottomed at -$438.2 million in Q4 2025.
  • Average Common Equity over 5 years is -$176.4 million, with a median of -$148.5 million recorded in 2024.
  • Year-over-year, Common Equity soared 351.43% in 2023 and then crashed 1428.57% in 2024.
  • Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then grew by 2.75% to -$72.8 million in 2023, then tumbled by 248.52% to -$253.6 million in 2024, then plummeted by 72.79% to -$438.2 million in 2025, then increased by 23.1% to -$337.0 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at -$337.0 million, -$438.2 million, and -$422.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.